Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $229M — +1.3% growth in a single year.
What Could Go Wrong
01Patent cliff exposure with key NERLYNX composition-of-matter patents expiring between 2026-2030, creating generic competition risk within 4-8 years without pipeline replenishment
02Evolving HER2+ breast cancer treatment paradigm with antibody-drug conjugates (Enhertu) demonstrating superior efficacy, potentially marginalizing oral TKI approaches
03Regulatory and reimbursement pressure on specialty pharmaceutical pricing, particularly for products with established competition
04Single-product dependency with no meaningful pipeline diversification creates binary commercial risk
05Dominant competition from Roche (Herceptin, Perjeta, Kadcyla) and Daiichi/AstraZeneca (Enhertu) with superior clinical profiles and market access
06Biosimilar erosion of HER2-targeted therapy market reducing overall pricing and market size for extended adjuvant setting
07Clinical guideline evolution potentially narrowing NERLYNX's target patient population or positioning it as later-line therapy
08Near-zero operating and free cash flow ($0.0B TTM) despite reported profitability raises questions about cash generation sustainability and working capital dynamics
value - The stock attracts deep-value investors and special situations funds given 135% one-year return, low valuation multiples (1.6x P/S…
Rising interest rates create modest headwinds through higher discount rates applied to future cash flows…
Watch on earnings: NERLYNX total prescription volume (TRx) from IQVIA or Symphony Health data, Quarterly net product revenue and gross-to-net percentage trends, Operating cash flow generation and cash balance adequacy (current ratio 1.74x).
One Sentence Summary:
The bear case: patent cliff exposure with key nerlynx composition-of-matter patents expiring between 2026-2030.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
